PDF(Pubmed)
Abstract：
BACKGROUND: Staining tissue samples to visualise cellular detail and tissue structure is at the core of pathology diagnosis, but variations in staining can result in significantly different appearances of the tissue sample. While the human visual system is adept at compensating for stain variation, with the growth of digital imaging in pathology, the impact of this variation can be more profound. Despite the ubiquity of haematoxylin and eosin staining in clinical practice worldwide, objective quantification is not yet available. We propose a method for quantitative haematoxylin and eosin stain assessment to facilitate quality assurance of histopathology staining, enabling truly quantitative quality control and improved standardisation.
METHODS: The stain quantification method comprises conventional microscope slides with a stain-responsive biopolymer film affixed to one side, called stain assessment slides. The stain assessment slides were characterised with haematoxylin and eosin, and implemented in one clinical laboratory to quantify variation levels.
RESULTS: Stain assessment slide stain uptake increased linearly with duration of haematoxylin and eosin staining (r = 0.99), and demonstrated linearly comparable staining to samples of human liver tissue (r values 0.98-0.99). Laboratory implementation of this technique quantified intra- and inter-instrument variation of staining instruments at one point in time and across a five-day period.
CONCLUSIONS: The proposed method has been shown to reliably quantify stain uptake, providing an effective laboratory quality control method for stain variation. This is especially important for whole slide imaging and the future development of artificial intelligence in digital pathology.
METHODS: The stain quantification method comprises conventional microscope slides with a stain-responsive biopolymer film affixed to one side, called stain assessment slides. The stain assessment slides were characterised with haematoxylin and eosin, and implemented in one clinical laboratory to quantify variation levels.
RESULTS: Stain assessment slide stain uptake increased linearly with duration of haematoxylin and eosin staining (r = 0.99), and demonstrated linearly comparable staining to samples of human liver tissue (r values 0.98-0.99). Laboratory implementation of this technique quantified intra- and inter-instrument variation of staining instruments at one point in time and across a five-day period.
CONCLUSIONS: The proposed method has been shown to reliably quantify stain uptake, providing an effective laboratory quality control method for stain variation. This is especially important for whole slide imaging and the future development of artificial intelligence in digital pathology.
摘要：
背景：染色组织样本以显示细胞细节和组织结构是病理诊断的核心，但是染色的变化会导致组织样本的外观明显不同。虽然人类视觉系统擅长补偿污点变化，随着数字成像在病理学中的发展，这种变化的影响可能更深远。尽管苏木精和伊红染色在世界各地的临床实践中普遍存在，客观量化尚不可用。我们提出了一种定量苏木精和伊红染色评估的方法，以促进组织病理学染色的质量保证，实现真正的定量质量控制和改进的标准化。
方法：染色定量方法包括常规显微镜载玻片，其一侧贴有染色响应性生物聚合物膜，称为染色评估幻灯片。染色评估载玻片用苏木精和伊红表征，并在一个临床实验室中实施以量化变异水平。
结果：染色评估载玻片染色摄取随苏木精和伊红染色持续时间线性增加（r=0.99），并证明染色与人类肝脏组织样品呈线性可比性（r值0.98-0.99）。该技术的实验室实施在一个时间点和五天内量化了染色仪器的仪器内和仪器间变化。
结论：所提出的方法已被证明可以可靠地量化染色吸收，为污点变异提供了一种有效的实验室质量控制方法。这对于整个幻灯片成像以及未来人工智能在数字病理学中的发展尤其重要。
方法：染色定量方法包括常规显微镜载玻片，其一侧贴有染色响应性生物聚合物膜，称为染色评估幻灯片。染色评估载玻片用苏木精和伊红表征，并在一个临床实验室中实施以量化变异水平。
结果：染色评估载玻片染色摄取随苏木精和伊红染色持续时间线性增加（r=0.99），并证明染色与人类肝脏组织样品呈线性可比性（r值0.98-0.99）。该技术的实验室实施在一个时间点和五天内量化了染色仪器的仪器内和仪器间变化。
结论：所提出的方法已被证明可以可靠地量化染色吸收，为污点变异提供了一种有效的实验室质量控制方法。这对于整个幻灯片成像以及未来人工智能在数字病理学中的发展尤其重要。
